机器人、胸腔镜与开胸肺叶切除术治疗T2-3N0肺癌的淋巴结升级分期比较
基于美国国家癌症数据库24 257例临床T2-3N0M0非小细胞肺癌患者的回顾性研究,经逆概率加权后分析20 834例,比较机器人、胸腔镜与开胸肺叶切除术的淋巴结升级分期率及总生存。三种术式N1和N2升级率无显著差异,机器人及胸腔镜术后总生存优于开胸。
要点
- T2-3N0肺癌机器人、胸腔镜与开胸肺叶切除术的N1和N2淋巴结升级率无显著差异。
- 机器人及胸腔镜肺叶切除术的总生存优于开胸手术。
- 对隐匿淋巴结转移高概率人群,微创术式淋巴结评估效果与开胸相当。
核心结论
- 临床T2-3N0非小细胞肺癌患者中,机器人、胸腔镜与开胸肺叶切除术的N1和N2淋巴结升级率无显著差异,提示淋巴结评估效果相似。
- 该隐匿淋巴结转移高概率人群中,机器人及胸腔镜肺叶切除术后的总生存显著优于开胸肺叶切除术。
研究设计与样本
- 回顾性研究,分析美国国家癌症数据库(National Cancer Database)中24 257例临床分期T2-3N0M0非小细胞肺癌患者。
- 采用逆概率加权(IPTW)平衡基线特征,比较不同手术方式的病理淋巴结升级率,并以Cox多变量回归模型检验与总生存的关联。
主要发现
- IPTW调整后纳入20 834例,其中机器人肺叶切除术1996例、胸腔镜肺叶切除术5122例、开胸肺叶切除术13 725例,手术年份为2010年至2017年。
- IPTW调整后N1升级率:机器人11.79%、胸腔镜11.49%、开胸11.85%(P = .274)。
- IPTW调整后N2升级率:机器人5.03%、胸腔镜5.66%、开胸6.15%(P = .274)。
- IPTW调整后多变量分析显示,机器人及胸腔镜肺叶切除术与开胸肺叶切除术相比总生存改善(P < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There may be equivalent efficacy of the lymph node evaluation for minimally invasive lobectomy compared with open lobectomy for stage I non-small cell lung cancer. We sought to compare the lymph node evaluation for lobectomy by approach for patients with larger tumors who are clinically node negative. METHODS: This retrospective study analyzed 24 257 patients with clinical stage T2-3N0M0 non-small cell lung cancer from the National Cancer Database. Inverse probability of treatment weighting (IPTW) was applied to balance baseline characteristics. The rates of pathologic lymph node upstaging were compared. A Cox multivariable regression model was performed to test the association with overall survival. RESULTS: After IPTW adjustment 20 834 patients were included in the analysis. Of these, 1996 patients underwent robotic lobectomy, 5122 patients underwent thoracoscopic lobectomy, and 13 725 patients underwent open lobectomy from 2010 to 2017. The IPTW-adjusted N1 upstaging rate was similar for robotic (11.79%), thoracoscopic (11.49%), and open (11.85%) lobectomy (P = .274). The adjusted N2 upstaging rates were 5.03%, 5.66%, and 6.15% for robotic, thoracoscopic, and open lobectomy, respectively (P = .274). On IPTW-adjusted multivariable analysis, robotic and thoracoscopic lobectomy were associated with improved survival compared with open lobectomy (P < .001). CONCLUSIONS: There was no significant difference in N1 and N2 lymph node upstaging rates between surgical approaches for patients with clinical stage T2-3N0 non-small cell lung cancer, indicating similarly effective lymph node evaluation. Overall survival after robotic and thoracoscopic lobectomy was significantly better compared with open lobectomy in this patient population with a high propensity for occult nodal disease.
引用
- Merritt RE, Abdel-Rasoul M, D'Souza DM, et al. Lymph Node Upstaging for Robotic, Thoracoscopic, and Open Lobectomy for Stage T2-3N0 Lung Cancer. Ann Thorac Surg. 2022. PMID: 35714729. doi:10.1016/j.athoracsur.2022.05.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。